Open AccessOmalizumab in patients with NSAIDs-exacerbated respiratory disease
Author(s) -
Ulrike FörsterRuhrmann,
Dafni Stergioudi,
Greta Pierchalla,
Joachim W. Fluhr,
KarlChristian Bergmann,
Heidi Olze
Publication year - 2020
Publication title -
rhinology (amsterdam. online)/rhinology
Language(s) - English
Resource type - Journals
eISSN - 1996-8604
pISSN - 0300-0729
DOI - 10.4193/rhin19.318
Subject(s) - medicine , omalizumab , nasal polyps , asthma , sinusitis , gastroenterology , surgery , immunoglobulin e , antibody , immunology
The association of acetylsalicylic acid (ASA) intolerance, chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, or chronic urticaria is known as NSAID-exacerbated respiratory disease (N-ERD). N-ERD patients often suffer from recurrent nasal polyps, severe asthma or also from urticaria. The aim of the present study was to retrospectively analyze the clinical efficacy of anti-IgE antibody treatment with omalizumab in patients with confirmed N-ERD.